Long-term Control of Rheumatoid Arthritis: Oral Targeted Agent Shows Sustained Advantage Over Biologic

SELECT-PsA 1 & SELECT-PsA 2: Oral Targeted Therapy for PsA Promises Efficacy in Bio-Naïve and Refractory Patients

Selective JAK Inhibitors Tested for Control of Psoriatic Arthritis

Practical Role of New Rheumatoid Arthritis Therapy Outlined in Expanded Data

Novel JAK Inhibitor Shows Efficacy over 48 Weeks of Treatment for Long-Term Control of Rheumatoid Arthritis

Phase 3 Data with New JAK Inhibitor in Rheumatoid Arthritis Predicts Evolving Sequence of Therapies

Oral JAK Inhibitors May Displace Injectable Biologics in Treatment of Rheumatoid Arthritis

Patient Support Program Helps Sustain Low Disease Activity on TNF Inhibitor Therapy

bDMARDs Improve Vascular Function in Treatment-naïve Patients with Early Rheumatoid Arthritis